MedTrace Logo

Diabetic Macular Edema Treated With Ozurdex (DMEO)

NCT01951066 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2016-09-29

Study results available
· View outcomes & findings →

Summary

To measure various pro-permeability factors in the aqueous humor of patients with persistent/recurrent diabetic macular edema

Conditions

Interventions

DRUG

Dexamethasone Implant

Patients will receive a single injection of a dexmethasone implant

DRUG

Anti-VEGF injection

Patients will receive PRN injections of an anti-VEGF agent

Sponsors & Collaborators

Principal Investigators

  • Peter A Campochiaro, MD · Johns Hopkins University

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01951066 on ClinicalTrials.gov